Call Us: 1.800.873.5297


VTE Risk in NuvaRing (Updated)

On May 10, 2012, the British Medical Journal published a new follow-up study by Dr. Øjvind Lidegaard entitled “Venous Thrombosis in Users of Non-Oral Hormonal Contraception: Follow-Up Study, Denmark 2001-10.” Øjvind Lidegaard et al., Venous Thrombosis in Users of Non-Oral Hormonal Contraception: Follow-Up Study, Denmark 2001-10, 344 BRIT. MED. J. 2990 (2012), available at The study analyzed the relative risk of venous thrombosis events (VTE) in 1,626,158 women from 2001 to 2010. It concluded that the relative risk of VTE in users of vaginal rings was 6.5 times higher than non-users of hormonal contraception, and 1.9 times higher than users of combined oral contraceptives.

NuvaRing is a vaginal contraceptive product of the kind referenced in this study. It was approved by the Food and Drug Administration (FDA) in 2001, and is composed of two active components: the progestin etonogestrel, and the estrogen ethinyl estradiol. Drug Approval Package: NuvaRing, U.S. FOOD & DRUG ADMIN. (Nov. 8, 2001), available at

Dr. Lidegaard’s conclusions are not new as “[a] recent study reported a … higher risk of [VTE] in women using a vaginal ring.” See OFFICE OF SURVEILLANCE & EPIDEMIOLOGY, U.S. FOOD & DRUG ADMIN., CHC-CVD-111022, COMBINED HORMONAL CONTRACEPTIVES (CHCS) AND THE RISK OF CARDIOVASCULAR DISEASE ENDPOINTS (2011), available at Dr. Lidegaard’s study, therefore, further clarified the existing statistics linking the NuvaRing to VTE. Taking these statistics in collectively, there is ample evidence demonstrating the potential adverse effects the NuvaRing may have on women.

Rapid responses to Dr. Lidegaard’s article were published by Dr. Samuel Shapiro, Dr. Jane Skov, Dr. Anne Szarewski, Dr. Julie M. Chandler, and Dr. Mary E. Gaffield. Some of these authors have been affiliated with the pharmaceutical industry. It is unclear whether the critics of Dr. Lidegaard’s article reviewed the study or its data in detail prior to posting their “rapid responses,” all of which were posted only days after Dr. Lidegaard’s study was published.

At this time, despite this study, the NuvaRing label states “[i]t is unknown if NuvaRing has a different risk of venous thromboembolism than second generation oral contraceptives.” It is unclear whether the manufacturer of NuvaRing intends to update its label in accordance with this study’s findings in the near future.

Attorneys at Schlichter Bogard & Denton have extensive knowledge in the NuvaRing litigation as they are members of the Multidistrict Litigation (MDL) Executive Committee, and represent clients from around the country. Attorneys at Schlichter Bogard & Denton also represent women in the YAZ birth control pill litigation, and have represented women in the Ortho Evra birth control patch litigation. If you or someone you know has been injured by NuvaRing or any other form of birth control, please contact the attorneys at Schlichter Bogard & Denton to discuss your case.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.